Telocyte Newsletter, Q1 2023: A Small Step Toward a Far Better World

The last few months at Telocyte have been remarkable. As a result of our 2020 article on age-related neurological disease and our December 2022 article on age-related cardiovascular disease, a lot has happened.

We have been actively recruited to chair or to give opening plenary keynote addresses at dozens of global conferences, including the event depicted above. In general, the conferences have been – just as we are – focused on the potential for curing and preventing Alzheimer’s and other dementias, but we have been open to other academic conferences as well, as long as the content is rigorous and science-based. We are and will remain selective in our choice of conferences with an eye on promoting our approach, validating our science, and encouraging future investment. With that in mind, I invite you to join us at the Global Longevity Federation conference in Dubai (electronically or otherwise) this coming May. Likewise, our new CSO (Rajesh Shukla) and I will co-chair the upcoming conference on Advancing Gene Therapy in Boston this June, in addition to my presentating at several other global neurology conferences later this year.

Perhaps more exciting for us has been the changes in our executive board, which I invite you to look at in detail on our website (under “Leadership Team”). These changes are in preparation for our program launch, as they increase our expertise in managing clinical trials, provide for secure data management, and add both rigor and credibility to our efforts. Our chief pharmaceutical officer (Radi Julina) has had decades of experience as a global executive for Roche, as well as leading human trials on Alzheimer’s disease and serving as the managing director of a global pharmaceutical investment firm, Pharma Capital Partners. Our chief scientific officer (Rajesh Shukla) was the senior medical director at Pfizer, has extensive experience with human trials and the FDA, and consults for SSI Strategy. Our operating officer (Michelle Hylan) brings international experience in clinical programs, trial design, biotechnology, pharmaceutical industry, and management, as well as extensive contacts in the biotechnology world. Our chief technical officer (Georgi Gospodinov) brings a lifetime of experience managing data security at large national corporations and has a practical knowledge of engineering, analytics, security, blockchain, and technology.

Most important, however, are the increasingly positive funding prospects. Our new executive team has raised significant interest from prospective investors. We are excited to be working with a new investor group who are equally excited about our program and our clinical goals. These goals are not only summarized in the papers cited above, but in our upcoming medical textbook, to be published later this year by Elsevier Publishing, for which I am both editor and senior author, Aging: How Aging Works, How We Can Reverse Aging, and Prospects for Curing Aging Diseases. I am joined by other authors from UCSF, MD Anderson, Mayo Clinic (5 authors), Swansea University, University of Innsbruck (2 authors), Detroit Medical Center, Wayne State School of Medicine, University of Wisconsin, Harvard Medical School, Houston Methodist, and the Grigore T. Popa University of Medicine & Pharmacology.

We look forward to sharing more information when we can, but the primary importance remains what it always has been and always will be for Telocyte: the ability to take our work to human trials and demonstrate that we can cure Alzheimer’s disease.

A small step toward a far better world.